D'Vaz A P, Ostor A J K, Speed C A, Jenner J R, Bradley M, Prevost A T, Hazleman B L
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge University NHS Trust, Cambridge, UK.
Rheumatology (Oxford). 2006 May;45(5):566-70. doi: 10.1093/rheumatology/kei210. Epub 2005 Nov 22.
Pulsed low-intensity ultrasound therapy (LIUS) has been found to be beneficial in accelerating fracture healing and has produced positive results in animal tendon repair. In the light of this we undertook a randomized, double-blind, placebo controlled trial to assess the effectiveness of LIUS vs placebo therapy daily for 12 weeks in patients with chronic lateral epicondylitis (LE).
Patients with LE of at least 6 weeks' duration were recruited from general practice, physiotherapy and rheumatology clinics, and had to have failed at least one first-line treatment including non steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid injection. Participants were assigned either active LIUS or placebo. Treatment was self-administered daily for 20 min over a 12-week period. The primary end-point was a 50% improvement from baseline in elbow pain measured at 12 weeks using a patient-completed visual analogue scale.
Fifty-five subjects aged 18-80 were recruited over a 9-month period. In the active group 64% (16/25) achieved at least 50% improvement from baseline in elbow pain at 12 weeks compared with 57% (13/23) in the placebo group (difference of 7%; 95% confidence interval -20 to 35%). However, this was not statistically significant (chi(2) = 0.28, P = 0.60).
In this study LIUS was no more effective for a large treatment effect than placebo for recalcitrant LE. This is in keeping with other interventional studies for the condition.
已发现脉冲低强度超声疗法(LIUS)有助于加速骨折愈合,并且在动物肌腱修复中取得了积极成果。鉴于此,我们进行了一项随机、双盲、安慰剂对照试验,以评估LIUS与安慰剂疗法每日治疗12周对慢性外侧上髁炎(LE)患者的有效性。
从全科医疗、物理治疗和风湿病诊所招募病程至少6周的LE患者,且这些患者必须至少对包括非甾体抗炎药(NSAIDs)和皮质类固醇注射在内的一种一线治疗无效。参与者被分配接受活性LIUS或安慰剂治疗。在12周的时间里,患者每天自行进行20分钟的治疗。主要终点是使用患者完成的视觉模拟量表在12周时测量的肘部疼痛较基线改善50%。
在9个月的时间里招募了55名年龄在18 - 80岁之间的受试者。在活性治疗组中,64%(16/25)的患者在12周时肘部疼痛较基线至少改善了50%,而安慰剂组为57%(13/23)(差异为7%;95%置信区间为 - 20%至35%)。然而,这在统计学上并不显著(χ² = 0.28,P = 0.60)。
在本研究中,对于难治性LE,LIUS在产生较大治疗效果方面并不比安慰剂更有效。这与针对该病症的其他干预性研究结果一致。